Variables | Preintervention n=100 | Postintervention (after 6 months use) n=100 | P value |
Demographics and comorbidities | |||
Mean age±SD | 40.64±13.93 | 39.92±15.04 | 0.71 |
Mean age of onset±SD | 26.10±12.23 | 27.66±13.60 | 0.38 |
Female, n | 55 (55%) | 54 (54%) | 0.88 |
Race, n* | |||
Caucasian | 95 (95%) | 83 (83%) | 0.006 |
Other (Asian, African-American) | 5 (5%) | 17 (17%) | |
Body mass index (BMI), kg/m2 mean±SD | 28.22±6.62 | 28.98±7.42 | 0.45 |
Family history of IBD, n | 39 (39%) | 35 (35%) | 0.55 |
Surgery (total or partial colectomy), n | 41 (41%) | 33 (33%) | 0.24 |
Steroid use, n | 22 (22%) | 17 (17%) | 0.37 |
Comorbid conditions, n | |||
Chronic heart disease | 8 (8%) | 2 (2%) | 0.05 |
Chronic kidney disease | 4 (4%) | 1 (1%) | 0.17 |
Diabetes mellitus | 3 (3%) | 4 (4%) | 0.70 |
Chronic liver disease | 2 (2%) | 3 (3%) | 0.65 |
Chronic lung disease* | 0 | 6 (6%) | 0.01 |
Chronic alcohol abuse | 3 (3%) | 0 | 0.08 |
Type of immunotherapy | |||
Oral 5-aminosalicyclic acid, n | 29 | 12 | |
Immunomodulators, n | 33 | 19 | |
Anti-TNF alpha therapy, n | 55 | 53 | |
Integrin receptor antagonists, n | 20 | 25 | |
Interleukin-12 and interleukin-23 antagonist n (%) | 1 | 17 | |
Quality measures outcomes | |||
Positive smoking history* | 14 (14%) | 21 (21%) | 0.02 |
Smoking cessation recommendation* | 11 (76%) | 21 (100%) | |
Influenza vaccination received* | No: 3 (3%) Unknown: 66 (66%) Yes: 31 (31%) | No: 27 (27%) Unknown: 5 (5%) Yes: 68 (68%) | <0.00005 |
Influenza vaccination recommendation | Yes: 90 (90%) No: 10 (10%) | Yes: 95 (95%) No: 5 (5%) | 0.17 |
PPSV 23 vaccination received* | No: 2 (2.4%) Yes: 34 (41%) Unknown: 47 (57%) n/a: 17 | No: 24 (25%) Yes: 64 (67%) Unknown: 8 (8.3%) n/a: 4 | <0.00005 |
PCV 13 vaccination received* | No: 2 (2.4%) Yes: 34 (41%) Unknown: 47 (57%) n/a: 17 | No: 23 (24%) Yes: 64 (67%) Unknown: 9 (9.4%) n/a: 4 | <0.00005 |
Pneumonia vaccine recommendation | Yes: 72 (87%) No: 11 (13.3%) n/a: 17 | Yes: 86 (90%) No: 10 (10.4%) n/a: 4 | 0.55 |
TPMT enzyme activity* | Yes: 19 (56%) Unknown: 14 (42.4) n/a: 67 | Yes: 18 (95%) Unknown: 1 (5.3%) n/a: 81 | 0.004 |
Hepatitis B screening* | Yes: 48 (60%) Unknown: 32 (40%) n/a: 20 | Yes: 91 (97%) No: 3 (3.2%) n/a: 6 | <0.00005 |
TB testing* | Yes: 10 (12.5%) Unknown: 70 (87.5%) n/a: 20 | Yes: 93 (99%) No: 1 (1%) n/a: 6 | <0.00005 |
DEXA scan recommendation | Yes: 34 (49%) Unknown: 36 (51.4%) n/a: 30 | Yes: 50 (77%) No: 13 (20%) n/a: 35 Unknown: 2 (3%) | <0.00001 |
Colon cancer screening | No: 2 (2%) Yes: 97 (98%) n/a: 1 | No: 1 (1.3%) Yes: 74 (98.7%) n/a: 25 | 0.73 |
Vitamin D documentation* | Yes: 83 (83%) No: 17 (17%) | Yes: 96 (96%) No: 4 (4%) | 0.002 |
*P<0.05 signifies statistical difference.
IBD, inflammatory bowel diseases; PCV 13, Pneumococcal Vaccine 13; PPSV 23, Pneumococcal Polysacharide Vaccine 23; TNF, tumour necrosis factor; TPMT, thiopurine methyltransferase.